Company

ScreenFect GmbH was founded in 2012 by Dr Pavel Levkin and Dr Gary Davidson as the result of a successful interdisciplinary research collaboration at the Karlsruhe Institute of Technology (KIT), Germany. Innovative chemistry in Dr Levkin's group combined with the biological and cell screening expertise in Dr Davidson's group allowed rapid transfer of technology from an academic setting to a commercial business.

With new patented technologies ScreenFect GmbH continues to expanding their repertoire of novel chemicals and reagents for the transfection of diverse cells. Sales and distribution are promoted by a growing list of worldwide partners.